Pacer Advisors Inc. Lowers Holdings in Kenvue Inc. (NYSE:KVUE)

Pacer Advisors Inc. lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 18.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 156,212 shares of the company’s stock after selling 34,966 shares during the period. Pacer Advisors Inc.’s holdings in Kenvue were worth $3,335,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of KVUE. Novare Capital Management LLC raised its position in Kenvue by 6.2% during the fourth quarter. Novare Capital Management LLC now owns 491,970 shares of the company’s stock valued at $10,504,000 after acquiring an additional 28,616 shares in the last quarter. Anderson Hoagland & Co. purchased a new position in shares of Kenvue during the 4th quarter valued at approximately $1,656,000. Juncture Wealth Strategies LLC lifted its stake in shares of Kenvue by 60.5% in the 4th quarter. Juncture Wealth Strategies LLC now owns 16,713 shares of the company’s stock valued at $357,000 after purchasing an additional 6,302 shares during the period. GSB Wealth Management LLC boosted its holdings in Kenvue by 0.9% during the fourth quarter. GSB Wealth Management LLC now owns 149,322 shares of the company’s stock worth $3,188,000 after buying an additional 1,323 shares in the last quarter. Finally, Geneos Wealth Management Inc. acquired a new stake in Kenvue during the fourth quarter valued at $29,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $21.72 on Friday. The company has a market cap of $41.64 billion, a P/E ratio of 39.48, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company’s 50-day moving average price is $22.00 and its 200-day moving average price is $21.85. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue was down .4% on a year-over-year basis. During the same period last year, the company posted $0.31 EPS. On average, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.78%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is currently 149.09%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Barclays lowered their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. JPMorgan Chase & Co. boosted their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. UBS Group dropped their price target on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. Finally, Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.